JP2003500067A - 少なくとも１つの疾患に対する患者の遺伝的疾病素質の分析法およびその方法に適応する増幅 - Google Patents
少なくとも１つの疾患に対する患者の遺伝的疾病素質の分析法およびその方法に適応する増幅Info
- Publication number
- JP2003500067A JP2003500067A JP2000620127A JP2000620127A JP2003500067A JP 2003500067 A JP2003500067 A JP 2003500067A JP 2000620127 A JP2000620127 A JP 2000620127A JP 2000620127 A JP2000620127 A JP 2000620127A JP 2003500067 A JP2003500067 A JP 2003500067A
- Authority
- JP
- Japan
- Prior art keywords
- drb1
- probe
- seq
- allele
- alleles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 51
- 230000003321 amplification Effects 0.000 title claims abstract description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 41
- 201000010099 disease Diseases 0.000 title claims abstract description 39
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 title description 13
- 239000000523 sample Substances 0.000 claims abstract description 163
- 230000002068 genetic effect Effects 0.000 claims abstract description 36
- 108091093088 Amplicon Proteins 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 156
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims description 155
- 108700028369 Alleles Proteins 0.000 claims description 153
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 16
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 13
- 108010061486 HLA-B27 Antigen Proteins 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 102000012153 HLA-B27 Antigen Human genes 0.000 claims description 9
- 229930010555 Inosine Natural products 0.000 claims description 9
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 9
- 229960003786 inosine Drugs 0.000 claims description 9
- 101150000578 HLA-B gene Proteins 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 208000027932 Collagen disease Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 101150044325 DRB1 gene Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 28
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 102000006390 HLA-B Antigens Human genes 0.000 description 12
- 108010058607 HLA-B Antigens Proteins 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 238000005457 optimization Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 5
- 238000001823 molecular biology technique Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 2
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- YFNXWBPNBVLTMB-UHFFFAOYSA-N 2-bromo-2-nitro-1,4-dioxane Chemical compound [O-][N+](=O)C1(Br)COCCO1 YFNXWBPNBVLTMB-UHFFFAOYSA-N 0.000 description 1
- 101000775252 Arabidopsis thaliana NADPH-dependent oxidoreductase 2-alkenal reductase Proteins 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- 101001041031 Homo sapiens Lariat debranching enzyme Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100021155 Lariat debranching enzyme Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000037855 acute anterior uveitis Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/06599 | 1999-05-20 | ||
| FR9906599A FR2793808B1 (fr) | 1999-05-20 | 1999-05-20 | Procede d'analyse de la predisposition genetique d'un patient a au moins une maladie |
| FR9915314A FR2793809B1 (fr) | 1999-05-20 | 1999-12-06 | Procede d'analyse de la predisposition genetique d'un patient a au moins une maladie et amplification adaptee a un tel procede |
| FR99/15314 | 1999-12-06 | ||
| PCT/FR2000/001385 WO2000071750A1 (fr) | 1999-05-20 | 2000-05-19 | Procede d'analyse de la predisposition genetique d'un patient a au moins une maladie et amplification adaptee a un tel procede |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500067A true JP2003500067A (ja) | 2003-01-07 |
| JP2003500067A5 JP2003500067A5 (enExample) | 2010-06-24 |
Family
ID=26234969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620127A Ceased JP2003500067A (ja) | 1999-05-20 | 2000-05-19 | 少なくとも１つの疾患に対する患者の遺伝的疾病素質の分析法およびその方法に適応する増幅 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7060438B1 (enExample) |
| EP (1) | EP1179091B2 (enExample) |
| JP (1) | JP2003500067A (enExample) |
| CN (1) | CN1351672A (enExample) |
| AT (1) | ATE279535T1 (enExample) |
| AU (1) | AU772175B2 (enExample) |
| BR (1) | BR0010739A (enExample) |
| CA (1) | CA2374440A1 (enExample) |
| DE (1) | DE60014887T3 (enExample) |
| ES (1) | ES2230109T5 (enExample) |
| FR (1) | FR2793809B1 (enExample) |
| WO (1) | WO2000071750A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2829580B1 (fr) | 2001-09-07 | 2004-02-13 | Bio Merieux | Procede de lecture, de detection ou de quantification, hybrides ou complexes utilises dans ce procede et biopuce mettant en oeuvre ledit procede |
| WO2004047007A1 (en) | 2002-11-15 | 2004-06-03 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| US7848889B2 (en) * | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
| FR2881437B1 (fr) | 2005-01-31 | 2010-11-19 | Biomerieux Sa | Procede pour le diagnostic/pronostic d'un syndrome septique |
| FR2906537A1 (fr) | 2006-09-28 | 2008-04-04 | Biomerieux Sa | Procede de diagnostic in vitro du cancer broncho-pulmonaire par detection des transcrits majoritaires alternatifs du gene klk8 codant la kallicreine 8 et son utilisation pour le pronostic de survie |
| US20130096024A1 (en) * | 2010-04-27 | 2013-04-18 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Method for detecting the susceptibility to develop adverse side effects related to bioimplants |
| EP2576815B1 (en) | 2010-06-04 | 2018-02-14 | Biomérieux | Method for the prognosis of colorectal cancer |
| US9110079B2 (en) | 2010-09-29 | 2015-08-18 | Biomerieux | Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS |
| WO2012129758A1 (en) | 2011-03-25 | 2012-10-04 | Biomerieux | Method and kit for determining in vitro probability for individual to suffer from colorectal cancer |
| EP3000897B1 (en) | 2013-05-21 | 2019-10-16 | Biomérieux | Colorectal cancer prognosis agent kit |
| EP3620984B1 (en) | 2018-09-06 | 2024-04-10 | Accenture Global Solutions Limited | Digital quality control using computer visioning with deep learning |
| WO2025172242A1 (en) | 2024-02-13 | 2025-08-21 | bioMérieux | Method of assessing the risk of death of a patient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06501622A (ja) * | 1991-07-17 | 1994-02-24 | ビオ メリウ | Ｈｌａ−ｄｒ型別判定の実施を可能にするプローブ系および該プローブを用いる型別判定法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567809A (en) * | 1986-03-13 | 1996-10-22 | Hoffmann-La Roche Inc. | Methods and reagents for HLA DRbeta DNA typing |
| US5468611A (en) * | 1990-06-27 | 1995-11-21 | The Blood Center Research Foundation, Inc. | Method for HLA typing |
| NL9002259A (nl) * | 1990-10-17 | 1992-05-18 | Eurodiagnostics B V | Werkwijze voor het bepalen van een genotype door het vergelijken van de nucleotidensequentie van leden van een genfamilie, alsmede kit voor het opsporen van genetische variaties. |
| GB9024005D0 (en) | 1990-11-05 | 1990-12-19 | British Bio Technology | Process for amplifying nucleic acid |
| US5976789A (en) * | 1991-07-17 | 1999-11-02 | Bio Merieux | System of probes enabling HLA-DR typing to be performed, and typing method using said probes |
| JPH0690757A (ja) * | 1991-08-23 | 1994-04-05 | Kitasato Inst:The | Ｈｌａ−ｄｒタイピング用塩基配列群とそれを用いた ｈｌａ−ｄｒタイピング法 |
| JPH08308596A (ja) * | 1995-03-10 | 1996-11-26 | Wakunaga Pharmaceut Co Ltd | Ｈｌａの検出 |
| US5939542A (en) | 1995-03-10 | 1999-08-17 | Wakunaga Seiyaku Kabushiki Kaisha | Detection of HLA-DR |
| WO1997020070A1 (en) * | 1995-11-29 | 1997-06-05 | The Anthony Nolan Bone Marrow Trust | Methods for separating and/or identifying dna molecules |
| FR2749308B1 (fr) * | 1996-06-03 | 1998-07-24 | Bio Merieux | Sondes nucleotidiques et procede pour determiner le typage hla dqb1 |
| AU6321998A (en) * | 1997-02-11 | 1998-08-26 | William H. Hildebrand | Class i sequence based typing of hla-a, -b, and -c alleles by direct dna sequencing |
| EP0887423A1 (en) * | 1997-06-26 | 1998-12-30 | Biotest Ag | A method for determining the Histocompatibility locus antigen class II |
| JP2001512694A (ja) * | 1997-08-11 | 2001-08-28 | ビジブル・ジェネティクス・インコーポレーテッド | Ｄｎａのｈｌａクラスｉタイプを決定するための方法およびキット |
| US5910413A (en) * | 1997-10-10 | 1999-06-08 | Visible Genetics, Inc. | Method and kit for amplification, sequencing and typing of classical HLA class I genes |
-
1999
- 1999-12-06 FR FR9915314A patent/FR2793809B1/fr not_active Expired - Fee Related
-
2000
- 2000-05-19 AU AU47660/00A patent/AU772175B2/en not_active Ceased
- 2000-05-19 WO PCT/FR2000/001385 patent/WO2000071750A1/fr not_active Ceased
- 2000-05-19 DE DE60014887T patent/DE60014887T3/de not_active Expired - Lifetime
- 2000-05-19 EP EP00929650A patent/EP1179091B2/fr not_active Expired - Lifetime
- 2000-05-19 CA CA002374440A patent/CA2374440A1/fr not_active Abandoned
- 2000-05-19 US US09/979,088 patent/US7060438B1/en not_active Expired - Fee Related
- 2000-05-19 ES ES00929650T patent/ES2230109T5/es not_active Expired - Lifetime
- 2000-05-19 AT AT00929650T patent/ATE279535T1/de not_active IP Right Cessation
- 2000-05-19 JP JP2000620127A patent/JP2003500067A/ja not_active Ceased
- 2000-05-19 BR BR0010739-5A patent/BR0010739A/pt not_active Application Discontinuation
- 2000-05-19 CN CN00807807A patent/CN1351672A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06501622A (ja) * | 1991-07-17 | 1994-02-24 | ビオ メリウ | Ｈｌａ−ｄｒ型別判定の実施を可能にするプローブ系および該プローブを用いる型別判定法 |
Non-Patent Citations (4)
| Title |
|---|
| JPN5002008042, ＫＩＭ Ｈ−Ｙ, ＡＮＮＡＬＳ ＯＦ ＴＨＥ ＲＨＥＵＭＡＴＩＣ ＤＩＳＥＡＳＥ, 1995, Ｖ５４, Ｐ９８８−９９０ * |
| JPN5002008044, ＥＶＡＮＳ Ｔ Ｉ, ＡＲＴＨＲＩＴＩＳ ＡＮＤ ＲＨＥＵＭＡＴＩＳＭ, 1995, Ｖ３８ Ｎ１２, Ｐ１７５４−１７６１ * |
| JPN6010000630, Ｈｕｍ．Ｉｍｍｕｎｏｌ．，Ｖｏｌ．３０（１９９１）ｐ．１９０−２０１ * |
| JPN6010000634, Ｉｍｍｕｎｏｇｅｎｅｔｉｃｓ，Ｖｏｌ．３６（１９９２）ｐ．２７７−２８２ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1179091A1 (fr) | 2002-02-13 |
| DE60014887T3 (de) | 2009-09-24 |
| AU772175B2 (en) | 2004-04-08 |
| ATE279535T1 (de) | 2004-10-15 |
| EP1179091B2 (fr) | 2009-02-25 |
| ES2230109T3 (es) | 2005-05-01 |
| EP1179091B1 (fr) | 2004-10-13 |
| BR0010739A (pt) | 2002-02-19 |
| AU4766000A (en) | 2000-12-12 |
| FR2793809B1 (fr) | 2006-07-28 |
| FR2793809A1 (fr) | 2000-11-24 |
| US7060438B1 (en) | 2006-06-13 |
| CA2374440A1 (fr) | 2000-11-30 |
| WO2000071750A1 (fr) | 2000-11-30 |
| CN1351672A (zh) | 2002-05-29 |
| ES2230109T5 (es) | 2009-06-05 |
| DE60014887T2 (de) | 2005-10-13 |
| DE60014887D1 (de) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6670124B1 (en) | High throughput methods of HLA typing | |
| JP3117083B2 (ja) | Ｈｌａ ｄｐタイプ分け方法 | |
| EP2281065A2 (en) | Method for evaluating and comparing immunorepertoires | |
| BR112012032586B1 (pt) | Métodos para determinar a sequência nucleotídica de um ácido nucléico de interesse e para determinar o genótipo hla em uma amostra | |
| IL194900A (en) | HLA allele gene associated with drug antagonism and methods for detecting it | |
| JP2003500067A (ja) | 少なくとも１つの疾患に対する患者の遺伝的疾病素質の分析法およびその方法に適応する増幅 | |
| Lank et al. | A novel single cDNA amplicon pyrosequencing method for high-throughput, cost-effective sequence-based HLA class I genotyping | |
| WO2011030159A1 (en) | Method using hla epitope determination | |
| Moyer et al. | Human leukocyte antigen (HLA) testing in pharmacogenomics | |
| JP3384806B2 (ja) | Ｈｌａ−ｄｒ型別判定の実施を可能にするプローブ系および該プローブを用いる型別判定法 | |
| JP2016516449A (ja) | Ｈｌａマーカーを使用する母体血液中の胎児ｄｎａ分率の決定方法 | |
| US20040014101A1 (en) | Separating and/or identifying polymorphic nucleic acids using universal bases | |
| JP2009261358A (ja) | Ｈｌａ−ｄｒｂ１遺伝子を含むヒト遺伝子のアレル多型のタイピング方法及びこれに用いるキット | |
| Koehler et al. | High‐throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real‐time PCR | |
| TW201300528A (zh) | Ｈｌａ－ｄｑｂ１基因分型的方法及其相關引子 | |
| ES2445709T3 (es) | Método para la identificación por técnicas moleculares de variantes genéticas que no codifican antígeno D (D-) y codifican antígeno C alterado (C+W) | |
| JP2000511430A (ja) | Ｈｌａ ｄｑｂ１タイピングを決定するためのヌクレオチドプローブおよび方法 | |
| US20040126794A1 (en) | Detection of susceptibility to autoimmune diseases | |
| Nathalang et al. | HLA‐B27 testing in Thai patients using the PCR‐SSP technique | |
| TWI579722B (zh) | 藥物不良反應風險評估方法及其裝置 | |
| JP5143450B2 (ja) | Ｈｌａ−ｂローカスにおける新規アリル | |
| Little | An overview of HLA typing for hematopoietic stem cell transplantation | |
| EP0910662A1 (en) | Methods and reagents for typing hla class i genes | |
| EP1816195A1 (en) | Nucleic acid fragments for detecting nucleic acid and method of detecting nucleic acid | |
| JP2010162020A (ja) | 新規ｈｌａ−ｄｒｂ１遺伝子およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100409 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100416 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100428 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100601 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20101026 |